BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on November 29.

The New York Times profiled the success story of a type 1 diabetes patient who was dosed with Vertex Pharmaceuticals’ experimental fully differentiated pancreatic islet cell replacement therapy, and after an infusion of VX-880, he began to produce his own insulin.

BioNTech SE said on Monday the company had started work on a vaccine tailored to Omicron, the worrying new coronavirus variant detected in South Africa.

With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened during 2021. And there are many! The accomplishments, opportunities and possibilities the scientific community has brought to bear, providing a way out of the COVID-19 pandemic and hope for the future of meaningful therapies for several challenging diseases, deserve a major shout-out.

Glympse Bio has developed a liquid biopsy with the potential to diagnose and monitor non-alcoholic steatohepatitis (NASH) with significantly higher accuracy and less invasiveness than needle biopsies, according to a late-breaking presentation at the American Association for the Study of Liver Disease (AASLD) annual The Liver Meeting.

Merck’s HIV strategy took a major hit as a “very important” aspect, MK-8507, was paused in development after patients experienced a low white blood cell count. East coast neighbor Enanta is also feeling the sting of a failed program with HBV trials, as the Massachusetts biotech is dropping the oral hepatitis B virus RNA destabilizer EDP-721 after healthy participants experienced safety signals.

A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response.

The U.S. Food and Drug Administration approved Covid-19 vaccine booster shots for all Americans ages 18 and over Friday morning.  

BridgeBio Pharma secured credit assistance worth as much as $750 million to move forward with the company’s research and development efforts for the treatment of cancers and genetic diseases.

Gilead Sciences exercised options to three of Arcus Biosciences’ programs, and the two companies also added a research collaboration deal.